Search Results

Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B.

SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer for SNB-101, a new drug for polymer nanoparticle anticancer under clinical trial.

Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy.

Affimed N.V. announced that the FDA has granted Fast Track designation to the combination of its innate cell engager AFM24 with atezolizumab for the treatment of patients with advanced and/or metastatic non-small cell lung cancer not harboring any activating EGFR mutations after progression on PD-1 targeted therapy and platinum-based chemotherapy.

Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

GenScript Biotech Corporation and Multiply Labs announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.

SN Bioscience Co., Ltd. announced on May 24 that European Medicines Agency had granted an orphan drug designation for small cell lung cancer, a rare disease, for SNB-101 which is a new polymer nanoparticle drug under development.